Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy.

doi:10.1136/jitc-2024-009541

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy.

Journal for immunotherapy of cancer - 22 Dec 2024

Kang Seounghun, Mansurov Aslan, Kurtanich Trevin, Chun Hye Rin, Slezak Anna J, Volpatti Lisa R, Chang Kevin, Wang Thomas, Alpar Aaron T, Refvik Kirsten C, Hansen O Isabella, Borjas Gustavo J, Berg Brendan T K, Shim Ha-Na, Hultgren Kevin T, Gomes Suzana, Wang Yue, Solanki Ani, Ishihara Jun, Swartz Melody A, Hubbell Jeffrey A

Abstract excerpt

BACKGROUND: The use of immune checkpoint inhibitors (CPIs) has become a dominant regimen in modern cancer therapy, however immune resistance induced by tumor-associated macrophages (TAMs) with immune suppressive and evasion properties limits responses. Therefore, the rational design of immune modulators that can control the immune suppressive properties of TAMs and polarize them, as well as dendritic cells (DCs),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Granulocyte-Macrophage Colony-Stimulating Factor

Share to Immunotherapy

Share to Interleukin-12

Share to Mice

Share to Mice, Inbred C57BL

Share to Tumor-Associated Macrophages

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 39794939
DOI: 10.1136/jitc-2024-009541
PMCID: PMC11667343

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy.PMID 39794939Read ↗

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responsesSemantic proximity Read ↗

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.Semantic proximity Read ↗

Genetically modified IL-2 bone marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironmentSemantic proximity Read ↗

Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases.Semantic proximity Read ↗

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read ↗

Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity.Semantic proximity Read ↗

Adverse prognosis of GM-CSF expression in human cutaneous melanomaSemantic proximity Read ↗

A Bacterial and Ganglioside-based Nanoparticle Initiates Reprogramming of Macrophages and Promotes Antitumor Phenotypes.Semantic proximity Read ↗

PD-L1 blockade restores CAR T cell activity through IFNγ-regulation of CD163+ macrophagesSemantic proximity Read ↗

Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy.Semantic proximity Read ↗

Modulating Tumor-Associated Macrophages through CSF1R Inhibition: A Potential Therapeutic Strategy for HNSCCSemantic proximity Read ↗

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.